With checkpoint inhibitors emerging as potential treatment approaches for advanced renal cell carcinoma, combining or sequencing them with vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors (TKIs) may reduce or delay disease progression, according to a recent review. Preliminary evidence suggests that VEGFR-TKIs can reverse immunosuppressive effects in the tumor microenvironment, potentially enhancing the effects of subsequent immunotherapy with checkpoint inhibitors. The authors discuss the potential role of first-line VEGFR-TKIs in priming the tumor microenvironment for immunotherapy.
Tannir N, Hammers H, Amin A. Impact of comorbidities on functional recovery from partial nephrectomy. [Published online ahead of print February 1, 2018]. Curr Med Res Opin. doi:10.1080/03007995.2018.1423960.
This Week's Must Reads
Does Integrated Delivery Treatment Impact Cost? , J Oncol Pract; ePub 2018 Feb 13; Kaye, Min, et al
Anticancer Agent Dose Rounding Cost Impact Assessed, J Oncol Pract; ePub 2018 Feb 5; Fahrenbruch, et al
Employment in Patients with Early-Stage BC Studied , Cancer; ePub 2018 Feb 13; Ekenga, Pérez, et al
Program’s Impact on CRC Screening in Uninsured , Cancer; ePub 2018 Feb 7; Eberth, Thibault, et al
Charting the Landscape of Oncology Pathway Vendors , J Oncol Pract; ePub 2018 Feb 7; Daly, Zon, et al
Must Reads in Renal Cell Carcinoma
Predicting RCC Outcomes After Surgery , Eur Urol; ePub 2018 Feb 2; Leibovich, et al
Partial vs Radical Nephrectomy Impact on Survival , Eur Urol Focus; ePub 2018 Feb 2; Marchioni, et al
Robotic Partial Nephrectomy for Large Renal Masses , BJU Int; ePub 2018 Jan 22; Delto, Paulucci, et al
Trends Examined in the Reporting of RCC Subtypes, Hum Pathol; ePub 2018 Jan 12; Gansler, et al
VEGFR Therapy’s Role in Reducing RCC Progression , Curr Med Res Opin; ePub 2018 Feb 1; Tannir, et al